TTL

Across TCGA pan-cancer cohorts, TTL mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TTL data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TTL mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TTL expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where TTL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	All	0.958	0.666	<.001	62	view →
CCRCC	DFS	Median	III,IV	0.200	0.739	<.001	16	view →
LUAD	OS	Tertile	III,IV	0.273	0.861	.003	15	view →
PDAC	DFS	Tertile	II,III,IV	0.243	0.653	.023	8	view →
HNSC	OS	Quartile	IV	0.866	0.550	.023	2	view →
GBM	OS	Tertile	All	0.342	0.515	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TTL–LSCC (OS)

Open the LSCC breakdown →